Needham & Company Reiterates a 'Buy' on Dyax Corp. (DYAX); The Company Continues to Focus on Building the Patient Base in HAE Orphan Indication For Long-Term Revenue Generation;
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Dyax Corp. (NASDAQ: DYAX), PT $8.
Needham analyst says, "Looking into 2011, we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Looking into 2011, we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
